Claims
- 1. A method for generating a CD8+ T cell immune response in a human against human immunodeficiency virus (HIV) comprising administering to said human at least one dose of each of the following:
(i) a priming composition comprising a source of one or more CD8+ T cell epitopes of HIV; and (ii) a boosting composition comprising a source of one or more CD8+ T cell epitopes of HIV, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, wherein the source of CD8+ T cell epitopes is a non-replicating or replication-impaired recombinant poxvirus vector in the human; with the proviso that if the source of epitopes in (i) is a viral vector, the viral vector in (ii) is derived from a different virus.
- 2. The method of claim 1 wherein the non-replicating or replication-impaired recombinant poxvirus vector is a recombinant vaccinia virus.
- 3. The method of claim 2 wherein the recombinant vaccinia virus is a recombinant MVA vector.
- 4. The method of claim 1 wherein the non-replicating or replication-impaired recombinant poxvirus vector is a recombinant avipox virus.
- 5. The method of claim 4 wherein the recombinant avipox virus is a recombinant fowlpox vector.
- 6. The method of claim 4 wherein the recombinant avipox virus is a recombinant canarypox vector.
- 7. The method of claim 6 wherein the recombinant canarypox vector is a recombinant ALVAC vector.
- 8. The method of claim 1 wherein the priming composition is a recombinant DNA plasmid.
- 9. The method of claim 1 wherein the priming composition is a viral vector.
- 10. The method of claim 9 wherein the viral vector is a herpes viral vector.
- 11. The method of claim 9 wherein the viral vector is a replicating viral vector.
- 12. The method of claim 9 wherein the viral vector is a non-replicating or replication-impaired viral vector.
- 13. The method of claim 1 wherein the boosting composition of (ii) is delivered intravenously, intraepideramlly, intramuscularly, subcutaneously or intradermally.
- 14. The method of claim 1 which further comprises administering an adjuvant.
- 15. The method of claim 1 wherein the CD8+ T cell epitopes are one or more epitope strings comprising an amino acid sequence selected from the group consisting of: SEQ ID Nos: 42, 43, 45-49, 51-53 and 55-64.
- 16. A method for generating a CD8+ T cell immune response in a human against human immunodeficiency virus (HIV) comprising administering to said human at least one dose of each of the following:
(i) a priming composition comprising a source of one or more CD8+ T cell epitopes of HIV, wherein the priming composition is a DNA plasmid; and (ii) a boosting composition comprising a source of one or more CD8+ T cell epitopes of HIV, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, wherein the source of CD8+ T cell epitopes is a non-replicating or replication-impaired recombinant vaccinia virus.
- 17. The method of claim 16 wherein the non-replicating or replication-impaired recombinant vaccinia virus is a recombinant MVA vector.
- 18. A method for generating a CD8+ T cell immune response in a human against human immunodeficiency virus (HIV) comprising administering to said human at least one dose of each of the following:
(i) a priming composition comprising a source of one or more CD8+ T cell epitopes of HIV, wherein the priming composition is a DNA plasmid; and (ii) a boosting composition comprising a source of one or more CD8+ T cell epitopes of HIV, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, wherein the source of CD8+ T cell epitopes is a recombinant avipox virus.
- 19. The method of claim 18 wherein the recombinant avipox virus is a recombinant fowlpox vector.
- 20. The method of claim 18 wherein the recombinant avipox virus is a recombinant canarypox vector.
- 21. The method of claim 20 wherein the recombinant canarypox vector is a recombinant ALVAC vector.
Priority Claims (1)
Number |
Date |
Country |
Kind |
GB9711957.2 |
Jun 1997 |
GB |
|
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser. No. 10/686,943, filed Oct. 16, 2003, which is a continuation of U.S. application Ser. No. 09/454,204, filed Dec. 9, 1999 (which issued as U.S. Pat. No. 6,663,871 B1), which is a continuation of International Application No. PCT/GB98/01681, which designated the United States and was filed Jun. 9, 1998, published in English, which claims priority under 35 U.S.C. §119 or 365 to Great Britain Application No. GB9711957.2 filed Jun. 9, 1997.
[0002] This application is also a continuation of U.S. application Ser. No. 10/653,624, filed Sep. 2, 2003, which is a divisional of U.S. application No. 09/454,204, filed Dec. 9, 1999 (which issued as U.S. Pat. No. 6,663,871 B1), which is a continuation of International Application No. PCT/GB98/01681, which designated the United States and was filed Jun. 9, 1998, published in English, which claims priority under 35 U.S.C. §119 or 365 to Great Britain Application No. GB9711957.2 filed Jun. 9, 1997.
[0003] The entire teachings of the above applications are incorporated herein by reference.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09454204 |
Dec 1999 |
US |
Child |
10653624 |
Sep 2003 |
US |
Continuations (5)
|
Number |
Date |
Country |
Parent |
10686943 |
Oct 2003 |
US |
Child |
10833745 |
Apr 2004 |
US |
Parent |
09454204 |
Dec 1999 |
US |
Child |
10686943 |
Oct 2003 |
US |
Parent |
PCT/GB98/01681 |
Jun 1998 |
US |
Child |
09454204 |
Dec 1999 |
US |
Parent |
10653624 |
Sep 2003 |
US |
Child |
10833745 |
Apr 2004 |
US |
Parent |
PCT/GB98/01681 |
Jun 1998 |
US |
Child |
09454204 |
Dec 1999 |
US |